Why New COVID Strains May Mean More Revenue for Pfizer and Moderna

Adria Cimino, The Motley Fool
·4-min read

In this Motley Fool Live video, recorded on Feb. 26, healthcare and cannabis bureau chief Corinne Cardina and Fool.com contributor Adria Cimino discuss how Pfizer (NYSE: PFE), Moderna (NASDAQ: MRNA), and others are faring, how they plan to deal with new variants, and what all of this means for revenue. Corinne Cardina: There has been a lot of different research about which vaccines, how they're holding up against different variants.